Nucleoside-modified RNA for Inducing an Adaptive Immune Response

Patent metadata

Field	Value
Publication number	US-2025064914-A1
Application number	US-202418925561-A
Country	US
Kind code	A1
Filing date	Oct 24, 2024
Priority date	Apr 27, 2015
Publication date	Feb 27, 2025
Grant date	—

Abstract

The present invention relates to compositions and methods for inducing an adaptive immune response in a subject. In certain embodiments, the present invention provides a composition comprising a nucleoside-modified nucleic acid molecule encoding an antigen, adjuvant, or a combination thereof. For example, in certain embodiments, the composition comprises a vaccine comprising a nucleoside-modified nucleic acid molecule encoding an antigen, adjuvant, or a combination thereof.

First claim

What is claimed is:

1 . A composition for inducing an adaptive immune response in a subject, the composition comprising at least one nucleoside-modified RNA molecule encoding at least one antigen, wherein the at least one antigen comprises at least one selected from the group consisting of a viral antigen, a bacterial antigen, a fungal antigen, a parasitic antigen, a tumor-associated antigen, and a tumor-specific antigen.

2 . The composition of claim 1 , wherein the at least one isolated nucleoside-modified RNA comprises pseudouridine.

3 . The composition of claim 1 , wherein the at least one isolated nucleoside-modified RNA comprises 1-methyl-pseudouridine.

4 . The composition of claim 1 , wherein the at least one antigen comprises an HIV antigen.

5 . The composition of claim 1 , wherein the nucleoside-modified RNA molecule comprises an mRNA molecule.

6 . The composition of claim 5 , wherein the wherein the mRNA molecule encoding the HIV antigen comprises a sequence of SEQ ID NO:2.

7 . The composition of claim 1 , wherein the composition further comprises an adjuvant.

8 . The composition of claim 1 , wherein the at least one nucleoside-modified RNA further encodes at least one adjuvant.

9 . The composition of claim 1 , further comprising a lipid nanoparticle (LNP).

10 . The composition of claim 9 , wherein the at least one nucleoside-modified RNA is encapsulated within the LNP.

11 . The composition of claim 1 , wherein the composition is a vaccine.

12 . A method of inducing an adaptive immune response in a subject comprising administering to the subject an effective amount of the composition of claim 1 .

13 . The method of claim 12 , wherein the composition is administered by a delivery route selected from the group consisting of intravenous, intradermal, subcutaneous, and intramuscular.

14 . The method of claim 12 , wherein the method comprises a single administration of the composition.

15 . The method of claim 12 , wherein the method comprises multiple administrations of the composition.

16 . The method of claim 12 , wherein the method treats or prevents at least one selected from the group consisting of a viral infection, a bacterial infection, a fungal infection, a parasitic infection, and cancer.

17 . The method of claim 12 , wherein the method treats or prevents HIV infection.

Assignees

• Univ Pennsylvania

Inventors

• Weissman Drew
• Pardi Norbert

Classifications

• C12N15/11

  DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity} · CPC title

• A61K31/712

  Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose · CPC title

• A61K31/7115

  Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine · CPC title

• A61K9/0019

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title

• A61P35/00

  Antineoplastic agents · CPC title